Clinical Trials Logo

Non-small Cell Carcinoma clinical trials

View clinical trials related to Non-small Cell Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02376699 Terminated - Lymphoma Clinical Trials

Safety Study of SEA-CD40 in Cancer Patients

Start date: February 28, 2015
Phase: Phase 1
Study type: Interventional

This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.